immuno-oncologynews.com

Immuno-Oncology News - The Web's Daily Resource for Immuno-Oncology News

Cancer Immunotherapy Based on Engineered Immune Cells as a Promising Approach Against Myeloma. Potential New Immunotherapy For Melanoma. Enhancing Anti-Tumoral Immunity by Inhibiting Specific Enzyme. Adoptive Cell ImmunoTherapy (ACT) - Advancing Personalised Cancer Treatment. Immune Checkpoint Protein Blockade And Low Dose Entire Body Irradiation Identified As Myeloma Immunotherapy. Phase I Study Finds Nivolumab Beneficial In Hodgkin's Lymphoma Patients. Potential New Immunotherapy For Melanoma. Celsion ...

http://www.immuno-oncologynews.com/

OVERVIEW OF immuno-oncologynews.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

21

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR IMMUNO-ONCOLOGYNEWS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

February

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Thursday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.5 out of 5 with 4 reviews

5 star

3

4 star

0

3 star

1

2 star

0

1 star

0

Hey there! Start your review of immuno-oncologynews.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

2.3 seconds

FAVICON PREVIEW

16x16
32x32
64x64
128x128

CONTACTS AT IMMUNO-ONCOLOGYNEWS.COM

3A ADVISORS, LLC

CHRIS COMISH

6360 LB●●●●●●●STE 200

DA●●AS , TEXAS, 75240

UNITED STATES

1.97●●●●2793

CB●@BIONEWS-TX.COM

View this contact

3A ADVISORS, LLC

CHRIS COMISH

6360 LB●●●●●●●STE 200

DA●●AS , TEXAS, 75240

UNITED STATES

1.97●●●●2793

CB●@BIONEWS-TX.COM

View this contact

BLUEHOST.COM

BLUEHOST INC

1958 S●●●●●●0 EAST

PR●●VO , UTAH, 84606

UNITED STATES

1.80●●●●9400

1.80●●●●1992

WH●●●@BLUEHOST.COM

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2014 July 10
UPDATED: 2014 July 10
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

9

YEARS
11

MONTHS
1

DAYS

NAME SERVERS

1: ns1.bluehost.com
2: ns2.bluehost.com

REGISTRAR

FASTDOMAIN, INC.

WHOIS : whois.fastdomain.com

REFERRED : http://www.fastdomain.com

CONTENT

PAGES IN
THIS WEBSITE

21

SSL

EXTERNAL LINKS

6

SITE IP

72.10.34.153

LOAD TIME

2.321 sec

SCORE

6.2

PAGE TITLE

Immuno-Oncology News - The Web's Daily Resource for Immuno-Oncology News | immuno-oncologynews.com Reviews

<META> DESCRIPTION

Cancer Immunotherapy Based on Engineered Immune Cells as a Promising Approach Against Myeloma. Potential New Immunotherapy For Melanoma. Enhancing Anti-Tumoral Immunity by Inhibiting Specific Enzyme. Adoptive Cell ImmunoTherapy (ACT) - Advancing Personalised Cancer Treatment. Immune Checkpoint Protein Blockade And Low Dose Entire Body Irradiation Identified As Myeloma Immunotherapy. Phase I Study Finds Nivolumab Beneficial In Hodgkin's Lymphoma Patients. Potential New Immunotherapy For Melanoma. Celsion ...

<META> KEYWORDS

1 immuno oncology

2 categories

3 t cells

4 melanoma

5 breast cancer

6 cancer vaccines

7 about us

8 immuno oncology news

9 follow

10 facebook

CONTENT

Page content here

KEYWORDS ON PAGE

immuno oncology,categories,t cells,melanoma,breast cancer,cancer vaccines,about us,immuno oncology news,follow,facebook,twitter,google,tumblr,breaking news,must reads,timeline,news,aug 7th,thomas jefferson,popular tags,acute lymphoblastic leukemia,cancer

SERVER

nginx

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Immuno-Oncology News - The Web's Daily Resource for Immuno-Oncology News | immuno-oncologynews.com Reviews

https://immuno-oncologynews.com

Cancer Immunotherapy Based on Engineered Immune Cells as a Promising Approach Against Myeloma. Potential New Immunotherapy For Melanoma. Enhancing Anti-Tumoral Immunity by Inhibiting Specific Enzyme. Adoptive Cell ImmunoTherapy (ACT) - Advancing Personalised Cancer Treatment. Immune Checkpoint Protein Blockade And Low Dose Entire Body Irradiation Identified As Myeloma Immunotherapy. Phase I Study Finds Nivolumab Beneficial In Hodgkin's Lymphoma Patients. Potential New Immunotherapy For Melanoma. Celsion ...

INTERNAL PAGES

immuno-oncologynews.com

1

Phase I Study Finds Nivolumab Beneficial In Hodgkin's Lymphoma Patients

http://immuno-oncologynews.com/2014/12/12/phase-study-finds-nivolumab-beneficial-hodgkins-lymphoma-patients

This is a short description about myself and what this site is about. I hope you enjoy being here! Phase I Study Finds Nivolumab Beneficial In Hodgkin’s Lymphoma Patients. December 12, 2014. December 12, 2014. By Patricia Inacio, PhD. A new study entitled PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. As a safe and efficient new treatment for patients with refractory or relapsed Hodgkin’s Lymphoma. The study was published in the. New England Journal of Medicine. The team obser...

2

Lilly and Immunocore Announce Collaboration To Evaluate Melanoma Drug

http://immuno-oncologynews.com/2015/07/01/lilly-immunocore-announce-collaboration-evaluate-melanoma-drug

This is a short description about myself and what this site is about. I hope you enjoy being here! Lilly and Immunocore Announce Collaboration To Evaluate Melanoma Drug. July 1, 2015. July 1, 2015. By Daniela Semedo, PhD. Recently announced they will collaborate in an immunotherapy-based clinical trial to evaluate the utility of Immunocore’s lead T cell receptor-based investigational drug called IMCgp100. Combined with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for melanoma. Immunocore&#...

3

Adoptive Cell immunoTherapy (ACT) - Advancing Personalised Cancer Treatment

http://immuno-oncologynews.com/2015/06/17/adoptive-cell-immunotherapy-act-advancing-personalised-cancer-treatment

This is a short description about myself and what this site is about. I hope you enjoy being here! Adoptive Cell ImmunoTherapy (ACT) – Advancing Personalised Cancer Treatment. June 17, 2015. June 17, 2015. By Patricia Inacio, PhD. In a special issue of the journal. A group of experts discuss the latest developments in adoptive cell immunotherapy. And new strategies to further enhance its use as a cancer treatment. Adoptive Cell ImmunoTherapy (ACT). Jonathan Wilkinson, Managing Commissioning Editor at.

4

Immune Checkpoint Protein Blockade And Low Dose Entire Body Irradiation As Myeloma Immunotherapy

http://immuno-oncologynews.com/2015/02/26/immune-checkpoint-protein-blockade-and-low-dose-entire-body-irradiation-identified-as-myeloma-immunotherapy

This is a short description about myself and what this site is about. I hope you enjoy being here! Immune Checkpoint Protein Blockade And Low Dose Entire Body Irradiation Identified As Myeloma Immunotherapy. February 26, 2015. February 26, 2015. According to a recent study published in the. Journal for Immunotherapy of Cancer. And titled “ Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma,. Researchers used a mouse model of multiple myeloma to te...

5

Activated Immune Cells Correlate With Promising Disease Outcome

http://immuno-oncologynews.com/2015/02/09/activated-immune-cells-correlate-promising-disease-outcome

This is a short description about myself and what this site is about. I hope you enjoy being here! Activated Immune Cells Correlate With Promising Disease Outcome. February 9, 2015. February 9, 2015. By Daniela Semedo, PhD. A research team from Heidelberg and Dresden discovered an important association between increased levels of TNF alpha. In colorectal tumor tissue and an increased number of activated cytotoxic T cells,. Journal of Clinical Investigation. The results revealed that high TNF alpha levels...

UPGRADE TO PREMIUM TO VIEW 16 MORE

TOTAL PAGES IN THIS WEBSITE

21

SOCIAL ENGAGEMENT

musculardystrophynews

md_today

OTHER SITES

immuno-onc.atpointofcare.com

@ Point of Care

immuno-onco.com

Ce domaine a été enregistré par Online.net

Ce domaine a été enregistré. Online est l'un des acteurs majeurs de l'hébergement en France. Créée en 2000 en même temps que le service d'accès à internet Free, nous sommes une filiale à 100% du groupe Iliad, focalisée sur les services d'hébergement Internet destinés aux webmasters et professionnels de l'internet. Êtes-vous le propriétaire de ce nom de domaine? Trouvez une solution d'hébergement pour votre domaine! Découvrez nos offres d'hébergements. Et de serveurs dédiés. Hébergez votre site web.

immuno-oncologiesymposium.nl

Multidisciplinair Immuno-Oncologie Symposium

T 31(0)73 690 14 15. F 31(0)73 690 14 17. Dinsdag 13 september 2016. 2e Multidisciplinair Immuno-Oncologie Symposium. Gezien het succes van afgelopen editie, is de programmacommissie trots om u te kunnen meedelen dat er ook dit jaar een Multidisciplinair Immuno- Oncologie Symposium georganiseerd wordt! Er 2 parallel sessies gepland staan met elk een eigen aandachtsgebied, te weten de medische oncologie en pulmonale oncologie. De bijeenkomst vindt plaats in de Prodentfabriek in Amersfoort. Deze locati...

immuno-oncology.org

7èmes Journées d'Immunologie & Immunothérapie des Cancers

9-11 décembre 2013 à Dijon. Ces journées sont biennales, les conférences données en français durent 30 min suivies de 15 min de discussion. Elles sont organisées par Jean-François Jeannin et le laboratoire d'immunologie et immunothérapie des cancers de l'EPHE (EA 7269 associée à l'INSERM UMR 866) assistés du service de formation continue de l'EPHE. Journées d'immunologie et immunothérapie des cancers. 9-11 décembre 2013, Dijon. Salle du conseil de la faculté des sciences Mirande.

immuno-oncologyeurope.com

Immuno Oncology Summit Europe

Final Agenda Now Available. Sponsorship and Exhibit Opportunities Available. Register Now for Maximum Savings. 160; . Tuesday, 21 March, 18:30-21:30. New Directions in Cancer Immunotherapy. CAR T and TCR Manufacturing Challenges to Anticipate and Overcome. Roy D Baynes, M.D., Ph.D. Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharp and Dohme. Zelig Eshhar, Ph.D. Chair, Cancer Immunotherapy, Research and Development, Sourasky Medical Center, Tel Aviv. Dario Neri, Ph.D. I believ...

immuno-oncologynews.com

Immuno-Oncology News - The Web's Daily Resource for Immuno-Oncology News

Cancer Immunotherapy Based on Engineered Immune Cells as a Promising Approach Against Myeloma. Potential New Immunotherapy For Melanoma. Enhancing Anti-Tumoral Immunity by Inhibiting Specific Enzyme. Adoptive Cell ImmunoTherapy (ACT) - Advancing Personalised Cancer Treatment. Immune Checkpoint Protein Blockade And Low Dose Entire Body Irradiation Identified As Myeloma Immunotherapy. Phase I Study Finds Nivolumab Beneficial In Hodgkin's Lymphoma Patients. Potential New Immunotherapy For Melanoma. Celsion ...

immuno-oncologysummit.com

Immuno Oncology Summit

JOIN US NEXT YEAR AT THE PREMIER ANNUAL IO EVENT. AUGUST 28-SEPTEMBER 1, 2017 SHERATON BOSTON HOTEL. Overall, this event provided a focused look at how researchers are applying new science and technology in the development of the next generation of effective and safe immunotherapies and the IO Summit Team is looking forward to 2017! If you have comments or suggestions for next year's program, please contact Samantha Drinkwater at 781-972-5461 or sdrinkwater@healthtech.com. Emerging Innate Immune Targets ...

immuno-onkologi.dk

Bristol-Myers Squibb immuno-onkologi

Derfor er I-O anderledes. Central T-Celleaktivering og hæmning. T-celle aktivering ved costimulatorisk signal. Perifer hæmning af T-celler. Hæmning og nedregulering af T-celler. I-O på tværs af cancerformer. Udforsk styrken ved immuno-onkologi. Bristol-Myers Squibb er dedikeret til forskning i immuno-onkologi. Bristol-Myers Squibb er førende globalt, når det gælder banebrydende forskning inden for immuno-onkologi (I-O). Se hvorfor I-O er anderledes. I-O på tværs af tumortyper. Lær mere om I-O.

immuno-onkologia.pl

Immuno-onkologia.pl - nowa strategia leczenia nowotworów

Nowotwory głowy i szyi. Nowotwory głowy i szyi. Leki i cząsteczki immunoonkologiczne. Na czym polega immunoterapia raka? Co to jest immunoonkologia? Jak działa nasz układ immunologiczny? Szlaki punktów kontroli układu odpornościowego: PD-1, CTLA-4. Przegląd prasy i aktualnych publikacji poświęconych immunoterapii nowotworów. Best of WCLC – 17th World Conference on Lung Cancer. Eksperci: immunoterapia skuteczna w niedrobnokomórkowym raku płuca. Immunoterapia nieoperacyjnego, zaawansowanego raka żołądka.

immuno-onkoloji.org

İmmuno Onkoloji Derneği

1 İmmuno-Onkoloji Kongresi'nden Yansımalar. Görsel Basın ) ). Yazılı Basın ) ). 2015 İmmüno - Onkoloji Derneği. Bu site BMS'in koşulsuz eğitim katkılarıyla hazırlanmıştır.

immuno-pet.info

Hover

This user has not enabled any redirections. Hover lets you easily create simple ways to access your digital life.